Niche Drug Delivery Aegis specializes in intravail oral, buccal, and intranasal delivery and ProTek excipients to improve stability and reduce immunogenicity of protein and peptide therapeutics, presenting sales opportunities for partnerships with biotech and pharma companies seeking non-invasive administration options and improved formulation.

Licensing Model The company commercializes its technologies through product-specific licenses, suggesting a business development angle focused on licensing deals, co-development opportunities, and strategic collaborations with larger biologics and peptide drug developers.

Acquisition History Aegis was acquired by Neurelis in 2018, indicating a potential alignment with neuroscience and specialty pharma portfolios and a path to leverage Neurelis’ networks and distribution channels for potential re-engagement or new licensing conversations.

Financial Scale With revenue under $1 million and a small team, there is a clear opportunity to pursue early-stage partnerships, grant-funded programs, or sponsored R&D collaborations to scale testing, formulation optimization, and proof-of-concept studies.

Technical Stack & Compliance Utilizing AWS, Drupal/WordPress, OneTrust, and security tools signals readiness for scalable digital engagement and regulatory/compliance considerations in bioscience licensing deals, enabling streamlined due diligence and partner onboarding.